BLUE MARCH - Colorectal Cancer Awareness Month
2024年1月26日
Is approximately the number of cases diagnosed annually, of which 520,000 are diagnosed in Europe. (1)
People diagnosed when the disease has already metastasised (stage IV).(2)
Estimated number of new cases globally per year by 2040. (3)
Colorectal cancer (CRC) is the third most common cancer worldwide with more than 1.9 million new cases in 2020.1 It is also the 2nd most deadly cancer in the world with over 930 000 deaths in 2020.2
Pierre Fabre commitment to colorectal cancer
As in previous years, Laboratoires Pierre Fabre are committed once again to raising public awareness of CRC prevention and screening, and to supporting the actions carried out by patient associations through the Blue March campaign "The wonderful colon".
The objective of “Wonderful Colon” campaign
Our objective is to invite the general public to take part in an immersive experience to discover this wonderful and not well-known organ and how to take care of it.
Through a deliberately positive and playful approach, the user will be able to learn more about how this organ works, why and how to take care of it, before tackling the subject of colorectal cancer, from its detection to its treatment.
It is important to raise awareness around reducing the risk and early diagnosis of CRC as early detection results in better outcomes than if diagnosed after the disease has metastasized.3
There are a range of everyday actions and activities that can help reduce the risk of colorectal cancer.4 Whatever their habits, lifestyle choices or individuality, everyone can do something to participate in CRC prevention and screening.
To learn more and take part in the diving experience, visit www.thewonderfulcolon.com/en
Our goal is still the same,
Every time we care for a single person, we make the whole world better
Références:
1. The Global Cancer Observatory, 2020. International Agency for Research on Cancer, World Health Organization. Available at: https://gco.iarc.fr/today/online-analysis-multi-bars. Accessed January 2024.
2. Van Cutsem E, et al. Ann Oncol. 2014;25(Suppl 3):iii1–iii9.
3. Gunter MJ, et al. Ann Oncol. 2019;doi: 10.1093/annonc/mdz044.
4. Kerr J, et al. Lancet Oncol. 2017; 18(8):e457–71. doi: 10.1016/S1470-2045(17)30411-4.
HQ--01-24-2400002